ChugaiCHUGAI PHARMACEUTICAL CO., LTD.4519東証プライム医薬品FY ending Dec 2023, consolidated, IFRS
Revenue changed -11.8% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and ending equity; net assets approximate parent equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2019 | 23.0% | 0.65× | 14.9% | 1.24× | 18.4% |
| 2020 | 27.3% | 0.69× | 18.7% | 1.25× | 23.4% |
| 2021 | 30.3% | 0.72× | 21.8% | 1.28× | 28.0% |
| 2022 | — | —× | 22.0% | —× | — |
| 2023 | 29.3% | 0.58× | 17.1% | 1.17× | 20.0% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2019 | FY ending Dec 2020 | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 |
|---|---|---|---|---|---|
| Revenue | 686,184 | 786,946 | 999,759 | 1,259,726 | 1,111,367 |
| Cost of revenue | 266,071 | 273,465 | 338,147 | — | — |
| Gross profit | 420,113 | 513,481 | 661,612 | — | — |
| SG&A | — | — | — | — | — |
| Operating income | 210,597 | 301,230 | 421,897 | — | — |
| Pretax income | 207,893 | 298,188 | 419,385 | 531,166 | 443,821 |
| Income tax | 50,333 | 83,455 | 116,390 | — | — |
| Net income attributable to owners | 157,560 | 214,733 | 302,995 | 374,429 | 325,472 |
| Operating margin | 30.7% | 38.3% | 42.2% | — | — |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
| Item | FY ending Dec 2019 | FY ending Dec 2020 | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥203.9B | ¥212.3B | ¥267.8B | ¥222.2B | ¥458.7B |
| Total assets | ¥1.06T | ¥1.24T | ¥1.54T | ¥1.87T | ¥1.93T |
| Net assets | ¥854B | ¥980B | ¥1.19T | — | ¥1.63T |
| Property, plant and equipment | ¥255.6B | ¥289.2B | ¥338.8B | — | — |
| Current assets | ¥699.7B | ¥834.9B | ¥1.06T | — | — |
| Total liabilities | ¥204.9B | ¥255.5B | ¥350.7B | — | — |
| Equity attributable to owners of parent | ¥854B | ¥980B | ¥1.19T | — | — |
EDINET (FSA Japan)
有価証券報告書－第115期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第114期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第113期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第112期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
訂正有価証券報告書－第111期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第110期(令和2年1月1日－令和2年12月31日)
Extracted from XBRL: 11 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.